Research programme: neurological disorders therapies - Aton Pharma

Drug Profile

Research programme: neurological disorders therapies - Aton Pharma

Alternative Names: AP-CNS21; AP-CNS24

Latest Information Update: 12 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aton Pharma; Merck & Co
  • Developer Merck & Co
  • Class
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Neurological disorders

Most Recent Events

  • 02 Apr 2004 Aton Pharma has been acquired by Merck & Co
  • 16 Apr 2003 Preclinical trials in Neurological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top